
Pulse Biosciences PLSE
$ 20.83
-1.61%
Annual report 2025
added 02-19-2026
Pulse Biosciences Interest Expense 2011-2026 | PLSE
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Pulse Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -52 K | -18 K | - | - | - | - | 983 K | 418 K | 247 K | 68 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 983 K | -52 K | 274 K |
Quarterly Interest Expense Pulse Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -19 K | - | - | - | -1 K | - | - | - | - | - | - | - | - | - | - | - | - | 517 K | 114 K | - | 9 K | 21 K | 78 K | 143 K | 218 K | 290 K | 332 K | 107 K | 118 K | 137 K | 56 K | 128 K | 39 K | 41 K | 39 K | 34 K | 31 K | 3 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 517 K | -19 K | 111 K |
Interest Expense of other stocks in the Medical instruments industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Ekso Bionics Holdings
EKSO
|
-26 K | $ 11.79 | -1.83 % | $ 28.6 M | ||
|
Atrion Corporation
ATRI
|
149 | - | - | $ 810 M | ||
|
iRhythm Technologies
IRTC
|
5.44 M | $ 120.8 | -6.47 % | $ 3.87 B | ||
|
Alcon
ALC
|
204 M | $ 74.09 | -1.04 % | $ 40.4 B | ||
|
Repro Med Systems
KRMD
|
9.91 K | $ 4.07 | 2.01 % | $ 188 M | ||
|
The Cooper Companies
COO
|
-16.4 M | $ 62.36 | -0.86 % | $ 12.4 B | ||
|
Envista Holdings Corporation
NVST
|
-2.3 M | $ 26.33 | 1.5 % | $ 4.42 B | ||
|
Masimo Corporation
MASI
|
300 K | $ 178.48 | 0.03 % | $ 9.51 B | ||
|
electroCore
ECOR
|
14.9 K | $ 6.64 | 2.0 % | $ 56.3 K | ||
|
Haemonetics Corporation
HAE
|
-9.75 M | $ 59.26 | -1.38 % | $ 2.98 B | ||
|
STAAR Surgical Company
STAA
|
2.25 M | $ 27.19 | 3.15 % | $ 1.35 B | ||
|
STERIS plc
STE
|
8.4 M | $ 214.4 | -1.14 % | $ 21.1 B | ||
|
ICU Medical
ICUI
|
93.3 M | $ 118.85 | -0.29 % | $ 2.93 B | ||
|
Teleflex Incorporated
TFX
|
57 M | $ 121.77 | -1.73 % | $ 5.43 B | ||
|
Isoray
ISR
|
2 K | - | 0.03 % | $ 108 M | ||
|
Glaukos Corporation
GKOS
|
13.6 M | $ 140.22 | -2.7 % | $ 6.79 B | ||
|
InfuSystem Holdings
INFU
|
1.4 M | $ 10.37 | 2.37 % | $ 214 M | ||
|
Microbot Medical
MBOT
|
2 K | $ 2.1 | 0.48 % | $ 96.2 M | ||
|
Utah Medical Products
UTMD
|
-120 K | $ 65.77 | 0.54 % | $ 213 M | ||
|
Milestone Scientific
MLSS
|
126 K | $ 0.34 | 9.03 % | $ 27.9 M | ||
|
Merit Medical Systems
MMSI
|
-2.39 M | $ 62.01 | -9.05 % | $ 3.67 B | ||
|
West Pharmaceutical Services
WST
|
-1 M | $ 300.68 | 1.04 % | $ 21.7 B | ||
|
DENTSPLY SIRONA
XRAY
|
24 M | $ 11.81 | 0.51 % | $ 2.35 B | ||
|
Retractable Technologies
RVP
|
227 K | $ 0.63 | 0.08 % | $ 18.9 M | ||
|
Pro-Dex
PDEX
|
533 K | $ 48.36 | -3.55 % | $ 159 M | ||
|
LeMaitre Vascular
LMAT
|
5.18 M | $ 112.04 | 2.09 % | $ 2.54 B | ||
|
Predictive Oncology
POAI
|
3 | - | - | $ 31.1 M | ||
|
BioLife Solutions
BLFS
|
497 K | $ 21.21 | 0.62 % | $ 977 M | ||
|
Stereotaxis
STXS
|
2 K | $ 1.93 | 3.21 % | $ 176 M | ||
|
Baxter International
BAX
|
290 M | $ 17.21 | -2.1 % | $ 8.83 B | ||
|
ResMed
RMD
|
3.2 M | $ 205.02 | -4.11 % | $ 29.9 B | ||
|
AtriCure
ATRC
|
683 K | $ 29.02 | 3.24 % | $ 1.39 B | ||
|
Harvard Bioscience
HBIO
|
-2.66 M | $ 6.36 | -0.31 % | $ 282 M | ||
|
AngioDynamics
ANGO
|
4.94 M | $ 11.16 | 2.01 % | $ 456 M | ||
|
Becton, Dickinson and Company
BDX
|
613 M | $ 149.31 | 0.13 % | $ 42.9 B | ||
|
Nephros
NEPH
|
2 K | $ 3.11 | -1.58 % | $ 32.3 M | ||
|
OraSure Technologies
OSUR
|
229 K | $ 2.95 | -2.96 % | $ 217 M | ||
|
Repligen Corporation
RGEN
|
8.12 M | $ 117.2 | -0.94 % | $ 6.53 M |